Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

A CDC vaccine advisory committee meeting scheduled for next week has been postponed. It was the first vaccine meeting since ...

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

The health secretary is planning to remove members of a panel that recommends vaccines if he sees conflicts of interest.

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...